Rochester General Hospital

Drs. James Iacobucci, Paul Burns, Edith Dale and Charis Lee Join National MDVIP Network to Provide Personalized, Preventive Care ROCHESTER, N.Y. and BOCA RATON, Fla., March 25, 2024 /PRNewswire/ -- MDVIP, the market leader in personalized healthcare with a network of over 1,100 physicians nationwide, today announced that it has partnered with four board-certified internists in Greater Rochester, New York. Dr. James J. Iacobucci, Dr. Paul Burns, Dr. Edith Dale and Dr. Charis A. Lee have opened MDVIP-affiliated practices and are currently accepting patients who seek more time and a closer relationship with their primary care doctor. James J. Iacobucci, M.D., a board-certified internist in Rochester, N.Y., has opened a new MDVIP-affiliated primary care practice. His office is located at 7255 State Route 96, Suite 210, in Victor. Paul Burns, M.D., a board-certified internist in Rochester, N.Y., has opened a new MDVIP-affiliated primary care practice. His office is located at 1815 South Clinton Avenue, Suite 620, in Rochester. Edith Dale, M.D., a board-certified internist in Rochester, N.Y., has opened a new MDVIP-affiliated primary care practice. Her office is located at 1815 South Clinton Avenue, Suite 620, in Rochester. Charis A. Lee, M.D., F.A.C.P., a board-certified internist in Rochester, N.Y., has opened a new MDVIP-affiliated primary care practice. Her office is located at 1815 South Clinton Avenue, Suite 620, in Rochester. James J. Iacobucci, M.D., earned his medical degree from the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, in New Brunswick, N.J. He completed his internship and residency in Internal Medicine at the University of Rochester-Strong Memorial Hospital. Dr. Iacobucci is a Diplomate of the American Board of Internal Medicine and is a licensed pharmacist. He is affiliated with Strong Memorial Hospital. His office is located at 7255 State Route 96, Suite 210, in Victor. Paul Burns, M.D., received his medical degree from the State University of New York at Buffalo, now known as the Jacobs School of Medicine and Biomedical Sciences. He performed his internship and residency in Internal Medicine at the University of Rochester. Dr. Burns is a Diplomate of the American Board of Internal Medicine and is affiliated with Rochester General Hospital. His office, Flower City Medical Group, is located at 1815 South Clinton Avenue, Suite 620, in Rochester. Edith Dale, M.D., received her medical degree and went on to complete both her internship and residency in Internal Medicine at the University of Rochester School of Medicine and Dentistry, where she served as chief resident. Dr. Dale is a Diplomate of the American Board of Internal Medicine and is affiliated with Rochester General Hospital. Her office, Flower City Medical Group, is located at 1815 South Clinton Avenue, Suite 620, in Rochester. Charis A. Lee, M.D., F.A.C.P., received her medical degree from St. George's University School of Medicine and completed her internship and residency in Internal Medicine at the University of Rochester Medical Center, where she was chief resident. Dr. Lee is a Diplomate of the American Board of Internal Medicine and a Fellow of the American College of Physicians. She is affiliated with Rochester Regional Health and the University of Rochester Medical Center. Her office, Flower City Medical Group, is located at 1815 South Clinton Avenue, Suite 620, in Rochester. "MDVIP is delighted to announce the addition of these highly respected internists in Rochester, where our network has had a presence since 2011," said MDVIP Chairman and CEO Bret Jorgensen. "Drs. Iacobucci, Burns, Dale and Lee each have decades of valuable clinical experience and recognize the importance of the doctor-patient relationship. Their affiliation with MDVIP will enable them to spend more time with patients on disease prevention and early detection and on developing tailored wellness plans that fit their lifestyle and health goals." MDVIP-affiliated physicians offer a solution to the many frustrations that patients can experience with traditional primary care, including long waits to schedule an appointment, rushed visits and difficulty getting all of their concerns addressed. By maintaining a smaller practice, doctors are able to dedicate more time with patients to focus on preventive care and early detection as well as help manage chronic conditions. Other conveniences include same- or next-day appointments that last an average of 30 minutes and 24/7 physician availability. Personalized Care For an annual membership fee, patients receive the MDVIP Wellness Program, a comprehensive yearly health assessment that includes advanced diagnostic tests and screenings to give a more complete view of the patient's overall health. Using the results, physicians provide ongoing coaching and tools to help patients make healthier lifestyle choices, prevent disease and achieve their wellness goals. Other benefits include the MDVIP Connect app and website, which allow patients to communicate with their doctor online, access personal health records and obtain meal plans, workout programs and other healthcare resources. Should an emergent need arise while a patient is traveling, physicians can help arrange care with a local hospital, pharmacy or doctor, which may include another MDVIP affiliate. Proven Health Outcomes Eleven peer-reviewed, published studies show that patients in MDVIP-affiliated practices have better health outcomes compared to those in traditional primary care practices, including: 79% fewer hospitalizations for Medicare patients, equating to $600 million savings in one year 72% fewer hospitalizations for commercially insured patients 40% more patients identified at risk for cardiovascular disease using advanced testing About MDVIP MDVIP leads the market in membership-based healthcare that goes far beyond concierge medicine services with a national network of more than 1,100 primary care physicians serving over 390,000 patients. For more information, visit . Follow MDVIP on Facebook, Instagram, Twitter and LinkedIn. Media Contact: Leslie Monreal-Feil 954.401.9931 [email protected] SOURCE MDVIP

DUBLIN--(BUSINESS WIRE)-- FIRE1 today announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2) of its FIRE1™ System for remote heart failure monitoring. The FIRE1 System is the first device designed to directly measure a patient’s volume status by measuring the largest vein in the body where most fluid is stored – the inferior vena cava (IVC) – to better manage heart failure. The FIRE1 study encompassed 15 patients treated at five centers across the U.S., including Austin Heart Central at the Heart Hospital of Austin, NewYork-Presbyterian/Columbia University Irving Medical Center, Duke University Medical Center, Rochester General Hospital, and The Ohio State University Wexner Medical Center. “Fluid build-up is challenging to accurately measure today and results in unnecessary hospital admissions due to fluid overload that was not caught early enough to be managed in the home,” said Dr. Nir Uriel, director of advanced heart failure and cardiac transplantation at NewYork-Presbyterian, and principal investigator of the study. “We are encouraged by our experience using the FIRE1TM system and excited about the prospect of heart failure management becoming easier and more effective for both patients and for the clinical team.” Dr. Uriel is also a professor of medicine in the Division of Cardiology at Columbia University Vagelos College of Physicians and Surgeons and an adjunct professor of medicine in the Greenberg Division of Cardiology at Weill Cornell Medicine. FIRE1 seeks to transform heart failure management by enabling patients to monitor and control their fluid volume themselves with a consumer-friendly device at home, similar to how continuous glucose monitoring transformed diabetes care. Fluid overload is a classic clinical feature of heart failure, which affects more than six million people in the U.S. and is the most common cause of hospitalization for those aged 65 and over. Today’s technologies do not directly measure fluid volume where it is primarily stored (the IVC), resulting in lagging measurements that do not identify fluid overload early enough to manage outside of the hospital. The FIRE1 system is a small, minimally invasive implantable sensor designed to accurately identify fluid build-up earlier, when it can be more easily managed by the patient and their physician without a hospital visit. “It is gratifying to see the physician interest in our novel technology that earlier studies suggest should be a more sensitive measure than pressure in monitoring heart failure,” said FIRE1 CEO and President Conor Hanley. “We look forward to sharing the results of this study with the clinical community and conducting larger studies to validate the performance of the FIRE1 device. By enabling patients to better manage their fluid load, we hope to unload the burden on emergency rooms, helping hospitals focus on the most urgent patients who need immediate care rather than on acute management of heart failure.” About FIRE1 Headquartered in Dublin, Ireland, FIRE1 is a connected medical device solutions company dedicated to improving outcomes for people suffering with chronic diseases. Its investors include Andera Partners, Gilde Healthcare, Gimv, the Ireland Strategic Investment Fund, Lightstone Ventures, Medtronic, New Enterprise Associates, Novo Holdings and Seventure. Its mission is to empower millions of people suffering from heart failure to get their normal lives back. FIRE1 is led by an experienced medical devices team working closely with world-leading researchers, clinicians, patients and payors to reduce the burden of heart failure. Further information: . More information about the Early Feasibility Study may be found on clinicaltrials.gov. Many physicians and scientists maintain relationships and collaborate with external organizations to foster scientific innovation and provide expert guidance. For more information, please see